thymoma
Conditions
Interventions
amrubicin and cisplatin
Sponsors
West Japan Oncology Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Histologically confirmation of invasive recurrent or metastatic thymoma Tumor has measureble lesion as per RECIST (v1.1). ECOG PS 0-1 Adult patient(>20 year of age) No previous chemotherapy and immunotherapy was received At least 4 weeks since prior surgery or radiation therapy. Adequate organ function. White blood cell count >= 4000/mm3 Absolute neutrophil count (ANC)>= 2000/mm3 and platelet count>= 100,000/mm3 Hemoglobin >= 10 gm/Dl Total bilirubin <= 1.5mg/dl AST, ALT must be <= 100IU/L Creatinine <= 1.5 mg/d PaO2 :>=60Torr Thymoma associated paraneoplastic syndrome was clinically controlled.
Exclusion criteria
Exclusion criteria: Other malignancy (exception: non-melanoma skin cancer, cervical carcinoma in situ, cancer without evidence more than 5 years since curative resection) pregnant, or lactating women active bacterial infection Severe, medical condition unstable cardiac disease despite of adequate management myocardial infarction within 6 months. Uncontorllable diabetes mellitus or hypertension or glaucoma. Interstitial lung diesease Active ulcer disease Continuers corticosteroids therapy. Uncontrolled Psychiatric problem which decrease treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, safety | — |
Countries
Japan
Contacts
Public ContactShinichiro Nakamura
West Japan Oncology Group WJOG datacenter
Outcome results
None listed